Worth reading
48Recurring
Scored from 5 of 6 sectionsDirection
Improvement
Direction inferred from the company’s description.Scale
83.1
Operating profit year-on-year change (%)Wording
Conditional
How definitive the wording is.Results for this period
First quarter1 April 2026 to 30 June 2026ConsolidatedJapanese GAAPNet Sales223,025¥ millionYear on year +12.3%Progress 27.2%
Operating profit14,944¥ millionYear on year +83.1%Progress 41.5%
Ordinary income13,750¥ millionYear on year +127.7%Progress 43.0%
Net income attributable to owners of the parent8,941¥ millionYear on year +109.8%Progress 28.4%
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
Net income per share¥148.46
Financial position at period-end
Total assets983,013¥ million
of which net assets 527,734 ¥ millionEquity ratio 51.3%vs. prior year-end -0.7pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Segment revenueMaterial Solutions Unit ¥94,444 million (YoY +14.7%), Quality of Life Solutions Unit ¥53,849 million (YoY +11.1%), Health Care Solutions Unit ¥22,026 million (YoY +20.5%), Nutrition Solutions Unit ¥52,434 million (YoY +6.3%)
Segment profitMaterial Solutions Unit ¥10,858 million (YoY +73.3%), Quality of Life Solutions Unit ¥7,006 million (YoY +34.5%), Health Care Solutions Unit ¥3,486 million (YoY +11.3%), Nutrition Solutions Unit ¥3,363 million (YoY +25.5%)
Outlook and shareholder returns
Full-year earnings forecast
Net Sales¥820,000 million (YoY +1.0%)
Operating profit¥36,000 million (YoY +9.4%)
Ordinary income¥32,000 million (YoY +10.8%)
Net income¥31,500 million (YoY +1.7%)
Annual Dividend Forecast¥160 → ¥210（+31.3%）
Factors Behind Changes in Business Performance
All business units reported increases in both revenue and profit, driven by price revisions in response to rising raw material costs, stable supply, expanded sales, a shift toward high-value-added products, and higher sales of Medical and Supplement products.
Disclosure regarding the going concern assumption
No applicable matters
Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 No
Changes in the scope of consolidationNew Number of companies 1 / Company name 株式会社カネカコリア / Excluded Number of companies 1 / Company name AB BIOTICS PTE.LTD.
Breakdown of extraordinary income (loss)Extraordinary income No / Extraordinary loss Litigation-Related Costs ¥330 million
Depreciation and amortization¥12,064 million
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingYes (for securities analysts and institutional investors)
Issued Shares at Period-End63,000,000
Treasury Shares at Period-End2,857,530
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 June 2026 |
| Net Sales | ¥223,025 million (YoY +12.3%) |
| Operating profit | ¥14,944 million (YoY +83.1%) |
| Ordinary income | ¥13,750 million (YoY +127.7%) |
| Profit attributable to owners of the parent | ¥8,941 million (YoY +109.8%) |
| Net income per share | ¥148.46 |
| Equity ratio | End of the current fiscal period 51.3 / End of previous period 52 |
| Total assets | ¥983,013 million |
| Net assets | ¥527,734 million |
| Full-year earnings forecast | Net Sales ¥820,000 million (YoY +1.0%) / Operating profit ¥36,000 million (YoY +9.4%) / Ordinary income ¥32,000 million (YoY +10.8%) / Net income ¥31,500 million (YoY +1.7%) |
| Annual Dividend Forecast | ¥160 → ¥210（+31.3%） |
| Segment revenue | Material Solutions Unit ¥94,444 million (YoY +14.7%), Quality of Life Solutions Unit ¥53,849 million (YoY +11.1%), Health Care Solutions Unit ¥22,026 million (YoY +20.5%), Nutrition Solutions Unit ¥52,434 million (YoY +6.3%) |
| Segment profit | Material Solutions Unit ¥10,858 million (YoY +73.3%), Quality of Life Solutions Unit ¥7,006 million (YoY +34.5%), Health Care Solutions Unit ¥3,486 million (YoY +11.3%), Nutrition Solutions Unit ¥3,363 million (YoY +25.5%) |
| Depreciation and amortization | ¥12,064 million |
| Breakdown of extraordinary income (loss) | Extraordinary income No / Extraordinary loss Litigation-Related Costs ¥330 million |
| Disclosure regarding the going concern assumption | No applicable matters |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New Number of companies 1 / Company name 株式会社カネカコリア / Excluded Number of companies 1 / Company name AB BIOTICS PTE.LTD. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Yes (for securities analysts and institutional investors) |
| Issued Shares at Period-End | 63,000,000 |
| Treasury Shares at Period-End | 2,857,530 |
| Factors Behind Changes in Business Performance | All business units reported increases in both revenue and profit, driven by price revisions in response to rising raw material costs, stable supply, expanded sales, a shift toward high-value-added products, and higher sales of Medical and Supplement products. |
Items this document does not state (12)
Operating MarginCash flows from operating activitiesCash flows from investing activitiesCash flows from financing activitiesCash and cash equivalents at end of periodRevision to Earnings ForecastPayout ratioShareholder Return PolicyRegional salesOrders received and order backlogImpairment lossMaterial subsequent events
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Price revisions in response to rising raw material costs, stable product supply, expanded sales across all areas, and a shift toward high-value-added products contributed to the increases in revenue and profit. In Health Care, expanded Medical sales, M&A, and the acquisition of new projects also began contributing to results.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.